GlassScriptPhysician profile
Matthew G Struttmann
NPI 1386676757
$7,192.78
in general payments reported to CMS, 2019-2025
42 companies · $2,696 in 2025
The $2,696 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $267 · 2021: $117 · 2022: $255 · 2023: $326 · 2024: $2,276 · 2025: $2,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,190 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,189.56 |
| Education | $108.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,621.58 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $852.20 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $681.65 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $592.64 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $415.60 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $282.97 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $258.24 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $226.33 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $220.47 | 2024-2025 | Zenpep, Vowst |
| Celltrion USA INC. | $163.42 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $162.31 | 2021-2025 | Ocaliva |
| Janssen Scientific Affairs, LLC | $151.98 | 2022 | |
| Celgene Corporation | $142.74 | 2023-2024 | Zeposia |
| Allergan, INC. | $124.41 | 2019 | |
| Genzyme Corporation | $122.16 | 2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Struttmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.